Vitiligo patients face lower skin cancer risk, but racial disparities emerge
A study of 123,000 patients found that people with vitiligo have significantly lower rates of skin cancer overall—particularly melanoma. However, preliminary findings suggest this protective effect may not apply equally across racial and ethnic groups, raising questions about underlying biological mechanisms and clinical screening practices.
Originaltitel: Vitiligo and skin cancer risk across racial/ethnic groups: A retrospective propensity score-matched study on 123,179 patients.
Vitiligo förändrar hudcancerrisken olika beroende på patienternas etniska bakgrund — ett fynd som framtvingar omvärdering av screening- och riskstratifieringsprotokoll inom dermatologi. En svensk-internationell forskargrupp från Karolinska Institutet analyserade 123 179 vitiligoöppna patienter från den amerikanska TriNetX-databasen. Resultatet visar att vitiligo sammantaget reducerar hudcancerrisken (HR 0,83) och särskilt melanomrisken (HR 0,69). Men explorativ analys avslöjar en motsatt trend: svarta/afroamerikanska patienter med vitiligo uppvisar faktiskt ökad risk för skivepitelcancer (HR 2,16). Denna etnisk variation kräver differentierad klinisk praxis. Läkemedelsutvecklare och diagnostikföretag måste anpassa risk-algoritmer till populationsheterogenitet. För bolag som investerar i hudcancerscreening eller präventiv dermatologiterapi öppnas nya segmentmöjligheter, men kräver större validering i diverse kohorter före marknadsplacering.
INTRODUCTION: The association between vitiligo and skin cancer has been previously studied, with most studies reporting either a reduced or no increased risk. However, findings remain inconsistent, and data on potential variation across ethnic groups remain limited. OBJECTIVE: The aim of this study was to investigate the association between vitiligo and the risk of skin cancer, and to explore whether this association varies by race/ethnicity. METHODS: A large-scale retrospective propensity score-matched study was conducted using real-world data from the TriNetX US Collaborative Network. A total of 123,179 patients with vitiligo were matched to an equal number of comparators. Outcomes were any skin cancer, including malignant melanoma, squamous cell carcinoma, and basal cell carcinoma. Several sensitivity analyses were performed to assess robustness in addition to subgroup analyses. RESULTS: The risk of any skin cancer was significantly lower in the vitiligo cohort compared with comparators (HR 0.83, 0.78-0.88, p = 0.002). The risk reduction was most pronounced for any malignant melanoma (HR 0.69, 0.58-0.81, p = 0.003). Exploratory subgroup analyses indicated a possible increased risk of squamous cell carcinoma in Black/African American individuals with vitiligo (HR 2.16, 1.09-4.28, p = 0.024). Sensitivity and control analyses were consistent. CONCLUSION: Vitiligo was associated with a reduced overall risk of skin cancer. However, the association varied by race/ethnicity, with a potentially increased risk observed among Black/African American patients. Further studies in diverse populations are warranted to confirm these findings.